(MENAFN- GlobeNewsWire - Nasdaq) SNS Insider Reports Steady Growth of the U.S. Asthma and COPD Drugs Market from USD 8.56 Billion in 2025E to USD 12.68 Billion by 2033, Supported by Awareness Programs, Expanding Biologic Usage, and Improved Access to Maintenance Treatments.Austin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Asthma and COPD Drugs Market Size & Growth Outlook
According to SNS Insider, the global Asthma and COPD Drugs Market is estimated at USD 33.16 billion in 2025 and is projected to reach USD 50.42 billion by 2033. The market is expected to grow at a CAGR of 5.42 percent during 2026 to 2033. The market is primarily driven by the increasing global prevalence of respiratory diseases, rising air pollution, an aging population, and significant advancements in treatment and drug delivery technologies
In the United States, the Asthma and COPD Drugs Market is estimated at USD 8.56 billion in 2025 and is forecast to reach USD 12.68 billion by 2033 at a CAGR of 5.07 percent. Growth is driven by rising disease prevalence, sustained adoption of long-term inhalation therapies, and broad clinical use of biologics in severe patient populations.
Request a Free Sample Report of the Asthma and COPD Drugs Market:
The market continues to benefit from early diagnosis programs, higher treatment adherence, and the availability of digitally enabled inhalers that support remote monitoring.
Market Overview
Asthma and chronic obstructive pulmonary disease remain two of the most widespread respiratory disorders worldwide. Air pollution, smoking, lifestyle factors, and aging populations continue to elevate the incidence of these conditions. As a result, demand for consistent, effective, and accessible treatment options has grown sharply.
Biologics, inhaled corticosteroids, long-acting bronchodilators, and single inhaler combination therapies have gained broad clinical acceptance. These therapies provide improved symptom control, enhanced adherence, and better long-term outcomes.
Across the United States, Europe, and Asia Pacific, governments and healthcare providers are ramping up initiatives focused on early detection and standardized management of chronic respiratory diseases. Pharmaceutical manufacturers are expanding development pipelines, investing in advanced inhaler technology, and scaling production of biologic agents to meet rising patient demand.
Key Companies Profiled in the Report
AstraZeneca PLC Boehringer Ingelheim GmbH GlaxoSmithKline PLC Novartis AG F. Hoffmann La Roche Ltd Pfizer Inc. Sanofi SA Merck and Co. Inc. Teva Pharmaceutical Industries Ltd Chiesi Farmaceutici SpA Azurity Pharmaceuticals Inc. Grifols SA Viatris Inc. Cipla Ltd Orion Corporation Regeneron Pharmaceuticals Inc. Amgen Inc. Sun Pharmaceutical Industries Limited Theravance Biopharma Inc. Verona Pharma PLC
Segmentation Analysis:
By Drug Type
Bronchodilators accounted for the largest share of 44.80% in 2025 due to their widespread use in relieving airway obstruction and improving breathing efficiency. The combined therapies emerged as the fastest-growing segment, registering a CAGR of 10.60% driven by enhanced efficacy, long-term management benefits, and rising adoption of single-inhaler combinations for improved patient compliance and treatment outcomes.
By Prescription Type
Prescription (Rx) drugs dominated the market with a 71.25% share in 2025 owing to the chronic nature of the diseases and the need for continuous physician monitoring. The over-the-counter (OTC) drugs exhibited the fastest growth at a CAGR of 9.20% as patients seek quick, accessible relief for mild respiratory symptoms.
By Disease Type
COPD led the market with a 58.40% share in 2025 due to its higher global prevalence, especially among aging and smoking populations. The asthma segment showed the highest growth potential, expanding at a CAGR of 8.90% driven by increasing cases among children and young adults, improved diagnostic practices, and growing access to advanced inhalation therapies, particularly in developing regions with rising respiratory health awareness.
By Distribution Channel
Retail pharmacies held the leading share of 48.75% in 2025 as they are the primary point of sale for both prescription and OTC drugs, providing convenience and immediate availability. The online pharmacies witnessing the fastest growth at a CAGR of 11.10% driven by increasing digitalization, telemedicine adoption, and home-delivery preferences.
Need Any Customization Research on Asthma and COPD Drugs Market, Enquire Now:
Regional Insights:
In 2025, North America dominated the Asthma and COPD Drugs Market and accounted for 36.58% of revenue share, this leadership is due to high disease prevalence, advanced healthcare systems, and strong presence of key pharmaceutical players.
Asia Pacific is expected to witness the fastest growth in the Asthma and COPD Drugs Market over 2026-2033, with a projected CAGR of 5.96% due to increasing pollution levels, smoking rates, and urbanization.
Recent Developments:
In March 2024, AstraZeneca partnered with Mankind Pharma in India to expand access to its inhaled corticosteroid-LABA combination therapy, improving asthma treatment availability and patient reach nationwide. In March 2024, Boehringer Ingelheim launched an out-of-pocket cap initiative, limiting inhaler costs to USD 35 monthly for eligible asthma and COPD patients, improving affordability and treatment adherence across the U.S.
Exclusive Sections of the Report (The USPs):
TREATMENT ADOPTION & THERAPY MIX METRICS – helps you understand regional usage patterns across inhaled, oral, injectable, and biologic therapies, revealing shifts in clinical preference and unmet needs. MEDICATION ADHERENCE & DIGITAL SUPPORT INDEX – helps you evaluate compliance levels for chronic maintenance treatments and measure the impact of digital inhalers and reminder tools on therapy adherence. HOSPITALIZATION & MORTALITY BURDEN INDICATORS – helps you assess regional hospitalization rates, exacerbation-related mortality, and the effectiveness of modern therapies in reducing acute episodes. INNOVATION & R&D INVESTMENT LANDSCAPE – helps you track annual R&D spending, clinical trial momentum, and development focus on biologics, combination drugs, and precision medicine solutions. THERAPEUTIC EFFECTIVENESS IMPROVEMENT SCORE – helps you analyze reductions in hospital admissions attributable to advanced drug therapies, supporting evaluation of treatment efficiency and healthcare impact.
Purchase Single User PDF of Asthma and COPD Drugs Market Report:
Asthma and COPD Drugs Market Report Scope
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email:...
Comments
No comment